Keryx: Patheon and Norwich sites will ensure supply of iron-based Auryxia
Keryx Biopharmaceuticals will continue to work with Norwich Pharmaceuticals despite bringing Patheon on board to manufacture Auryxia (ferric citrate).
Archives for March 6, 2017
CRO market in Asia to see 'significant increase' through 2020
The CRO market in Asia has “massive implications” as it continues to emerge as a preferred destination for clinical trials – a global market expected to reach $57bn by 2020.
Merck KGaA's Allergopharma opens production facility
Merck KGaA has opened a €42m production facility in Reinbek near Hamburg, Germany.
Nemus hires Catalent to formulate second chemo-induced nausea drug
Catalent Pharma Solutions has been hired to formulate Nemus Bioscience’s synthetic cannabinoid based chemotherapy induced nausea drug.
NIH extends PPD HIV research support contract until 2024
The renewed contract covers a range of research related services, including monitoring therapeutic trials, prevention trials, and vaccines work, with the ultimate goal of an "AIDS-free generation."
Mithra CDMO signs up a second Estrogen drug in 20-year Fuji deal
Mithra CDMO has entered a second agreement for Fuji Pharma to commercialise Donesta in Asia, another of Mithra’s estrogen-based hormone drugs.
WuXi subsidiary HD to use Irish cell-based assays to monitor Mitochondria
Irish Luxcel will grant access to its consumable in vitro cell toxicity tests to Shanghai-based CRO HD Biosciences to help reduce the risk of post-market drug withdrawal.
US Wockhardt subsidiary Morton Grove warned by US FDA
The US FDA has warned Wockhardt Limited about operations at its US subsidiary Morton Grove Pharmaceuticals Inc.
Safety implications of GCP loophole 'very concerning,' says IAOCR
IAOCR is lobbying for a change to current ICH-GCP Guidelines, which would help CROs “deliver strong, reliable trials efficiently.”